Jazz Pharmaceuticals will acquire biotech firm Chimerix for about $935 million in cash to gain access to its lead drug ...

It was bought new by the founder of Hawaiian Tropic, who quite obviously was living the Good Life in the '80s.

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 ...

Truist analyst Scot Ciccarelli raised the firm’s price target on Costco (COST) to $995 from $935 and keeps a Hold rating on the shares. The company delivered another strong quarter, and its ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

Jazz Pharmaceuticals plc is buying Chimerix Inc. for $8.55 a share in cash, bringing the deal in at about $935 million. Jazz ...

From 2019-2023, North Carolina increased the number of life sciences business establishments by 43%. To learn more in the TEConomy 2024 report, click here.

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...